Head and Neck Cancer Market Size is estimated to grow at a CAGR of 8.5% during the forecast period for 2025-2034.
According to the study published in NCBI (2014), head and neck cancer (HNC) is the sixth most common cancer worldwide, with an estimated 630,000 new cases every year. Specifically, this type of cancer includes tumors of the oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity. Tobacco and alcohol consumption is strongly associated with head and neck cancer.
Multiple factors that drive the head and neck cancer market include the increasing combination therapies for the management of head & neck cancer, rising prevalence of head and neck cancer, increasing adoption of advanced medical technologies, reduction in medical errors in cancer care, various government initiatives for various cancer therapy developments, and increasing awareness among people regarding the advanced cancer treatments. In addition, risk factors such as growth in cigarette smoking, alcohol intake & tobacco use are expected to fuel the market growth.
However, the high cost of treatments, the side effects of available therapies, and the lack of health coverage act as major restraints of this market.
The head and neck cancer market has been segmented on the basis of product and region. The products segment comprises of cytotoxic agents [Antimetabolites (Abitrexate/ Mexate/ Folex (methotrexate), hydrea (hydroxyurea), antitubulins, taxotere (docetaxel), others (Platinum Agents, Fluoropyrimidines), Platinol (cisplatin), 5-fluorouracil (5-FU)], EGFR Inhibitors [Erbitux (cetuximab), Vectibi (panitumumab), Theracim/Theraloc (nimotuzumab)], EGFR Inhibitors (TKIs) [Tarceva (erlotinib), Iressa (gefitinib), Tykerb/Tyverb (lapatinib)], PD1 Inhibitors [Keytruda (pembrolizumab), Opdivo (nivolumab)], Pipeline Drugs [EGFR Inhibitors (mAbs) (Vectibix (panitumumab)), PDL1 Inhibitors (Imfinzi (durvalumab), Bavencio (avelumab)), CTLA4 Inhibitors (Yervoy (ipilimumab), Tremelimumab)]. At regional level, the head and neck cancer market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The North American region is projected to hold the major market share in 2024, followed by Europe, Asia-Pacific, and Rest-of-the-World.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 8.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Advaxis, Inc. (US), Amgen, Inc. (US), AstraZeneca plc (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (US), Five Prime Therapeutics, Inc. (US), GlaxoSmithKline plc (UK), Incyte Corporation (US), IRX Therapeutics, Inc. (US), MacroGenics, Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics (US) among others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell Head and Neck Cancer Market Snapshot
Chapter 4. Global Cell Head and Neck Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Clinical Trial/Pipeline Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 3: By Products Estimates & Trend Analysis
5.1. By Products & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Cytotoxic Agents
5.2.1.1. Antimetabolites
5.2.1.1.1. Abitrexate/ Mexate/ Folex (methotrexate)
5.2.1.1.2. Hydrea (hydroxyurea)
5.2.1.2. Antitubulins
5.2.1.2.1. Taxotere (docetaxel)
5.2.1.3. Others (Platinum Agents, Fluoropyrimidines)
5.2.1.3.1. Platinol (cisplatin)
5.2.1.3.2. 5-fluorouracil (5-FU)
5.2.2. EGFR Inhibitors (mAbs)
5.2.2.1. Erbitux (cetuximab)
5.2.2.2. Vectibix (panitumumab)
5.2.2.3. Theracim/Theraloc (nimotuzumab)
5.2.3. EGFR Inhibitors (TKIs)
5.2.3.1. Tarceva (erlotinib)
5.2.3.1.1. Iressa (gefitinib)
5.2.3.2. Tykerb/Tyverb (lapatinib)
5.2.4. PD1 Inhibitors
5.2.4.1. Keytruda (pembrolizumab)
5.2.4.2. Opdivo (nivolumab)
5.2.5. Pipeline Drugs (Late-stage)
5.2.5.1. EGFR Inhibitors (mAbs)
5.2.5.1.1. Vectibix (panitumumab)
5.2.5.2. PDL1 Inhibitors
5.2.5.2.1. Imfinzi (durvalumab)
5.2.5.2.2. Bavencio (avelumab)
5.2.5.3. CTLA4 Inhibitors
5.2.5.3.1. Yervoy (ipilimumab)
5.2.5.3.2. Tremelimumab
Chapter 6. Cell Head and Neck Cancer Market Segmentation 5: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
6.1.2. North America Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
6.2. Europe
6.2.1. Europe Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.2.2. Europe Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.3. Asia Pacific
6.3.1. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.3.2. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) estimates and forecasts by Types, 2021-2034
6.3.3. Asia Pacific Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.4. Latin America
6.4.1. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.4.2. Latin America Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) By Products, 2021-2034
6.5.2. Middle East & Africa Cell Head and Neck Cancer Market revenue (US$ Million) by country, 2021-2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Advaxis, Inc.
7.2.2. Amgen, Inc.
7.2.3. AstraZeneca plc
7.2.4. Boehringer Ingelheim GmbH
7.2.5. Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.)
7.2.6. Cel-Sci Corporation
7.2.7. Five Prime Therapeutics, Inc.
7.2.8. GlaxoSmithKline plc
7.2.9. Incyte Corporation
7.2.10. IRX Therapeutics, Inc.
7.2.11. MacroGenics, Inc.
7.2.12. Merck KGaA
7.2.13. Novartis AG
7.2.14. Pfizer, Inc.
7.2.15. Roche Holdings AG (Genentech)
7.2.16. Viracta Therapeutics
7.2.17. Other Prominent Players
Global Head and Neck Cancer Market, by Products
Global Head And Neck Cancer Market, by Region
\North America Head and Neck Cancer Market, by Country
Europe Head and Neck Cancer Market, by Country
Asia Pacific Head and Neck Cancer Market, by Country
Latin America Head and Neck Cancer Market, by Country
Middle East & Africa Head and Neck Cancer Market, by Country
Competitive Landscape
Other Prominent Players